BioSpace News Archive

Precede Biosciences emerges from stealth with a breakthrough, comprehensive, blood-based approach to revealing disease-defining transcriptional biology – a first for the diagnostic field.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023.

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) is pleased to announce its participation in the Immunoglobulin National Society (“IGNS”) 2023 National Conference, taking place in Denver, Colorado from October 5th to 8th.

Study shows the DecisionDx-Melanoma test identifies more patients who can safely forego SLNB than using current guidelines alone or a clinicopathologic-only nomogram.

Axion BioSystems today announced the appointment of Julien Bradley as the company’s new Chief Executive Officer.

Bruush Oral Care Inc. today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market on October 2, 2023 that is has been granted an exception for continued listing on the Nasdaq.

Theralase Technologies Inc. is focused on the safe and effective destruction of various cancers, bacteria and viruses, when light or radiation activated.

SAB Biotherapeutics today announced that the SAB Board of Directors has approved the appointment of Andrew Moin to the Company’s Board of Directors.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will present data related to clinical study outcomes and its early access programs via both oral and poster presentations at the upcoming 52 nd Child Neurology Society (CNS) Annual Meeting.

BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics.